Wuxi Taxus Pharmaceutical Co., Ltd was established in 2004, and a bio-pharmaceutical company under the HODO Group which is the top 500 private enterprises. It is mainly engaged in the research, development, production and sales of paclitaxel-based anti-tumor drugs. The complete industrial chain was established, from the cultivation of yew resources to the processing of yew branches and leaves, paclitaxel primary products, paclitaxel series of raw materials and intermediates to preparations. Products include cabazitaxel, 10-DAB, dresian hydrochloride, allopurinol, L-5-methylfolate, L-5-methylfolate, etc. API, and paclitaxel injection.

The company has strong technical strength. In 2018, the company established the Hongdoushan International Pharmaceutical Research and Development Company in New York, focusing on the research and development and introduction of anticancer drugs. At present, the Hongdoushan research and development center hires the Doctor returned from abroad to lead the research and development of new products, and currently has more than 30 senior engineers. What's more, the R&D Center has established close cooperative relations with Jiangsu Academy of Agricultural Sciences, Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tsinghua University, and foreign research institutes.

The company's paclitaxel API has obtained the US DMF registration number (25759), and is registered in Korea, India, Iran, Russia, Belarus and other countries. It is sold at home and abroad, mainly exported to India, South America, Russia, Egypt and other countries and regions, and praised